Microbiome composition varies based on sampling time, mouse study finds
The microbiome has immense power to shape health outcomes. The bacteria that take up residence…
Category: microbiome
Why researchers think human milk could repair the gut microbiome and reduce infections
For babies who are breastfed, their first source of sustenance is filled with proteins, sugars,…
Gut bacteria could play role in kidney autoimmune disease, study shows
Right now, inside your digestive tract, there are trillions of bacteria, fungi, and viruses that…
STAT+: Evelo Biosciences, a microbiome company launched by Flagship, shuts down
Evelo Biosciences, a startup hoping to use the trillions of microbes in and on the…
FDA approves first microbiome drug from Ferring Pharmaceuticals
The Food and Drug Administration approved the first therapy using bacteria from stool samples to…
STAT+: Following your gut: How scientists are getting closer to linking the microbiome and chronic diseases
We never walk alone. Across the landscape of our bodies, trillions of microbes accompany us…
STAT+: Vedanta touts positive new data for its C. diff microbiome therapeutic — but is it too late?
Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C….
STAT+: FDA dings Kaleido Biosciences for testing a microbiome drug without proper paperwork
The Food and Drug Administration is warning Lexington, Mass.-based Kaleido Biosciences that it shouldn’t have…
STAT+: New research exploring centenarians’ gut microbiomes reveals a potential clue to their longevity
New research into the microbiomes of centenarians reveals a potential clue to their longevity, adding…
STAT+: Microbiome therapy companies face the fallout of failed Seres trial
A frost may be setting in across the microbiome therapeutics space after another clinical trial…
STAT+: Seres Therapeutics’ microbiome therapy for ulcerative colitis falls short in Phase 2 trial
Seres Therapeutics’ highly anticipated clinical trial in ulcerative colitis failed to meet its primary endpoint,…
STAT+: Nestle Health Science will split profits from Seres microbiome drug, if it’s approved
Seres Therapeutics has announced a new deal with its long-time partner, Nestle Health Science, to…
Watch: What’s the deal with fecal transplants?
For more than a decade, scientists have been experimenting with a procedure known as a…
STAT+: The field is exploding, but microbiome therapeutics still face a wave of challenges
Even as drug makers are poised to introduce actual medicines to change a person’s microbiome…
Opinion: STAT+: Developers of microbiome-based drugs face challenges. There are ways to overcome them
Manipulating the human microbiome appears to be an effective approach for treating a range of…
STAT+: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives
Microbiome company Finch Therapeutics is, officially, worth about $960 million. Shares in the company began…
SEC charges co-founders of shuttered microbiome startup uBiome with $60 million fraud
Federal authorities on Thursday charged two co-founders of uBiome, a microbiome startup that rose to…
STAT+: OpenBiome to wind down stool bank operations
OpenBiome, the nation’s first public stool bank, will soon end its program for collecting, screening,…
STAT+: Fecal matter transplants could help certain cancer drugs work in more people, study shows
Checkpoint inhibitors like Keytruda and Opdivo can be incredibly powerful cancer-killing drugs — when they…
STAT+: Months of limbo at OpenBiome put fecal matter transplants on hold across the country
New regulations put in place because of Covid-19 have left one of the largest U.S….
STAT+: New research underscores the link between multiple sclerosis and the gut microbiome
Researchers have uncovered more evidence that there is a link between a person’s gut microbiome,…
STAT Plus: Seres announces positive late-stage results for its microbe-based drug
Four years after a devastating clinical trial failure, Seres Therapeutics seems to have found success….
STAT Plus: Finch touts positive results for its microbiome pill for C. diff infections
Three-quarters of the people who got Finch Therapeutics’ microbe-based pill for potentially deadly C. difficile…
STAT Plus: A patient’s microbiome could have a major impact on how drugs affect them, new research confirms
The unique array of bacteria in a person’s gut can dramatically change how well they…
STAT Plus: Bacteria are widespread in tumors, forming distinct populations depending on the cancer type
In what outside experts called the most rigorous and comprehensive survey of bacteria in human…
STAT Plus: ‘Good’ bacteria could help fight a common vaginal infection, new data show
Most companies in the microbiome space have focused on recurrent, deadly C. difficile bacterial infections….
STAT Plus: Rebiotix unveils positive — but preliminary — data on its microbiome drug for C. diff infections
Rebiotix, one of a handful of major companies working on microbiome-based drugs, announced Wednesday that…
STAT Plus: Within months of birth, some pathogens are detectable in infants’ guts, new research shows
Bacteria have long been the star of microbiome research. But the human gut is not…
STAT Plus: CDC credits a sharp decline in C. diff infections to checklists and better antibiotic stewardship
The rate of Americans contracting potentially fatal Clostridium difficile bacterial infections in hospitals fell between…
STAT Plus: Despite coronavirus disruption, major microbiome companies are cautiously optimistic about upcoming data
This was supposed to be the microbiome’s breakthrough year — and pandemic or not, it…
Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer
The many companies developing liquid biopsies to try to detect cancer early have so far…
STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
The microbiome industry is on the cusp of a turning point. Seres Therapeutics, one of…
STAT Plus: Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation
Bankrupt microbiome-testing startup uBiome, once valued at $600 million by Silicon Valley investors, preliminarily sold…